Have you treated patients in 2012 with "novel cellular therapies" (i.e., related to non-hematopoietic cell types and indications)?

If so please complete the simple survey form (Click on PDF or Excel format) and send it to Helen Baldomero as soon as possible by e-mail: helen.baldomero@usb.ch or by fax: + 41 61 265 2735 and help have an effective impact on the scientific, clinical and regulatory aspects of cellular therapy.

Background to the survey
In 2008, 5 societies joined forces to establish a survey on "novel cellular therapies":

• the Tissue Engineering & Regenerative Medicine Society, European Chapter (TERMIS-EU),
• the International Society of Cellular Therapy, European Section (ISCT-Europe),
• the International Cartilage Repair Society, European Section (ICRS),
• the European group for Blood and Marrow Transplantation (EBMT) and
• the European League Against Rheumatism (EULAR).

The survey is designed to establish a comprehensive, quantitative map of which specific cell types, sorted by the cell processes and delivery mode, are being used to treat patients in Europe and to distribute this information rapidly. It also integrates the original EBMT "transplant activity survey", launched in 1990 to capture the number of patients transplanted with hematopoietic stem cells in Europe.

Deadline
31 August 2013

The survey only includes the number of treated patients, without any reference to their clinical outcome, and leads to a yearly publication, which presents the data, summarizes the trends and lists in the appendix the names of the participating teams.

Go to www.termis.org/chapters_eu_novel.php for more information.